DCLLSG

Recruiting Trials of the GCLLSG

First-Line Therapies for CLL

CLL17

A phase 3 multicentre, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukaemia (CLL)
» more

CLL-Frail

A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients with no more than one previous CLL treatment
» more

 

Therapies for relapsed/refractory CLL

CLL2-BZAG

A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and venetoclax (ABT-199) in patients with relapsed/refractory CLL
» more

CLL-Frail

A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients with no more than one previous CLL treatment
» more

 

Therapies for Richter Transformation

CLL-RT1

A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor, plus tislelizumab (BGB-A317), a PD1 inhibitor, for treatment of patients with Richter Transformation
» more